In a significant development for cardiac care, Kerendia, a drug crafted by Bayer, has recently gained FDA approval to treat heart failure patients classified with moderate ejection fraction, defined as having a left ventricular ejection fraction (LVEF) of at least 40%. This approval potentially
In the rapidly evolving landscape of pharmaceutical research, the integration of advanced technology with traditional methodologies is crucial for achieving breakthroughs in sustainable drug discovery. A prominent example of such integration is the collaboration between Optibrium and TalTech, which
Imagine transforming today's healthcare challenges through cutting-edge scientific discovery, where diseases like cancer and cardiovascular disorders are seen as mere puzzles to solve. Within this realm of possibilities, the focus turns toward SENP5, a protease with the potential to illuminate new
Amid rising prevalence and societal impact, addressing Alzheimer's disease demands breakthroughs in research and treatment. The pioneering initiative by the Indiana University School of Medicine, through the TREAT-AD (Target Enablement to Accelerate Therapy Development for Alzheimer's Disease) drug
With a wealth of experience in biopharma and a keen eye for technological advancement, Ivan Kairatov stands at the forefront of innovation in the industry. Today, he shares his insights on the FDA's recent decision to publish complete response letters (CRLs), a move designed to enhance transparency
The field of oncology is perpetually advancing, with innovative therapies constantly emerging to tackle complex diseases like lung cancer. Ivan Kairatov, a seasoned expert in biopharma with extensive experience in technological innovations and R&D, provides insights into the recent FDA approval of
